Illustrative image – not actual.Karnataka Antibiotics & Pharmaceuticals (KAPL) has drawn up plans to modernise its manufacturing facilities, over the next 3-4 years, with an investment of Rs.20 crore. This would help the company meet the raise domestic standards, needs of international clients and give a thrust to exports.
The Karnataka state-owned company also aims to shift its focus on the lifestyle segment of cardio-vascular, stress and diabetes management therapies. KAPL current product portfolio includes 12 non-antibiotic and 30 antibiotic drugs.
